Trial Profile

A retrospective observational study analyzing effectiveness and safety of conversion from twice-daily immediate-release tacrolimus or once-daily prolonged-release tacrolimus to the recent formulation once-daily MeltDose extended-release tacrolimus

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 29 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

29 Jan 2020 Primary endpoint (change in kidney function 3 months after the conversion to LCP-Tac, compared with 3 months before the conversion, using the estimated glomerular filtration rate (eGFR) as calculated with the CKD-EPI formula) has not met, according to results published in the Clinical Transplantation
29 Jan 2020 New trial record
09 Dec 2019 Results published in the Clinical Transplantation

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com